It’s my fault you’re missing a part of the sto
Post# of 36536
Josh is the Barron’s writer that Doc wrote to as noted in Doc’s prior posts. However, with Gnbt trading well under $1, typically they then are a publicly traded company that won’t be written about. Very often $1 is the lowest share price amount allowed to write a positive story about.
I hope we start to see Generex and NuGenerex promote themselves as well. Many small successful biotechs I follow still hit up investor events even if virtually. And hopefully that peer review mentioned last Fall comes to publication. All of that can help.